Optofluidic Bioassay was formed in 2015 to develop and commercialize an invention which was started in 2012 at the University of Michigan. The technology brings significant improvement to the conventional ELISA (enzyme-linked immunosorbent assay) test workflow.
Optofluidic Bioassay has developed and validated its novel microfluidic 96-well ELISA plate and has demonstrated superior results in sample/reagent size, workflow and assay time in ELISA tests in comparison with a standard 96-well plate. Optofluidic Bioassay’s one-of-a-kind, proprietary, microfluidic 96-well plate technology enables the end-user to realize significant improvements in speed and cost at equal or better sensitivity and dynamic range, as demonstrated in prototype test results. The benefit of using Optofluidic Bioassay’s microfluidic plate includes an 85% time savings per test by eliminating steps in the ELISA workflow at shorter reaction times and up to 80% cost savings by using only 20% of the sample/reagent size—all without requiring any modification to their current workflows or equipment.